Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;156(1):1-10.
doi: 10.1007/s11060-021-03807-6. Epub 2021 Jul 12.

Sonodynamic therapy for gliomas

Adomas Bunevicius  1 , Stylianos Pikis  1 , Frederic Padilla  2   3 , Francesco Prada  1   2   4 , Jason Sheehan  5   6
Affiliations
Review

Sonodynamic therapy for gliomas

Adomas Bunevicius et al. J Neurooncol. 2022 Jan.

Abstract

Introduction: Glioma remains incurable and a life limiting disease with an urgent need for effective therapies. Sonodynamic therapy (SDT) involves systemic delivery of non-toxic chemical agents (sonosensitizers) that accumulate in tumor cells or environment and are subsequently activated by exposure to low-frequency ultrasound to become cytotoxic agents. Herein, we discuss proposed mechanisms of action of SDT and provide recommendation for future research and clinical applications of SDT for gliomas.

Methods: Review of literature of SDT in glioma cell cultures and animal models published in Pubmed/MEDLINE before January, 2021.

Results: Different porphyrin and xanthene derivatives have proven to be effective sonosensitizers. Generation of reactive oxygen species and free radicals from water pyrolysis or sonosensitizers, or physical destabilization of cell membrane, have been identified as mechanisms of SDT leading to cell death. Numerous studies across glioma cell lines using various sonosensitizers and ultrasound parameters have documented tumoricidal effects of SDT. Studies in small animal glioma xenograft models have also consistently documented that SDT is associated with improved tumor control and longer survival of animals treated with SDT while avoiding damage of surrounding brain. There are no clinical trials completed to date regarding safety and efficacy of SDT in patients harboring gliomas, but some are beginning.

Conclusions: Pre-clinical studies cell cultures and animal models indicate that SDT is a promising treatment approach for gliomas. Further studies should define optimal sonication parameters and sonosensitizers for gliomas. Clinical trials of SDT in patients harboring gliomas and other malignant brain tumors are currently underway.

Keywords: Focused ultrasound; Glioma; Sonodynamic therapy.

PubMed Disclaimer

References

    1. Ostrom QT, Gittleman H, Truitt G et al (2018) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neurooncology 20:iv1–iv86. https://doi.org/10.1093/neuonc/noy131 - DOI
    1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 - DOI - PubMed
    1. Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085–4091. https://doi.org/10.1200/JCO.2013.49.6968 - DOI - PubMed - PMC
    1. Stupp R, Brada M, van den Bent MJ et al (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3:iii93–i101. https://doi.org/10.1093/annonc/mdu050
    1. Nam JY, de Groot JF (2017) Treatment of Glioblastoma. JOP 13:629–638. https://doi.org/10.1200/JOP.2017.025536 - DOI - PubMed

LinkOut - more resources